Autopsy report · NCT05393713

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

“low/slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8; Melanoma; Metastatic Melanoma; Recurrent Metastatic Melanoma

Interventions

Anti-PD-L1 Monoclonal Antibody IMC-001; Punch Biopsy

Participants

3

Sites

2

Countries

United States

Trials that died the same way

• Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
  “Slow accrual” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.